BCG
CYTK icon

Breakwater Capital Group’s Cytokinetics CYTK Stock Holding History

Breakwater Capital Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Hold
3,941
– – 0.04% 292
2026
Q1 		$260K Hold
3,941
– – 0.03% 322
2025
Q4 		$250K Buy
3,941
+2
+0.1% +$124 0.03% 309
2025
Q3 		$216K Buy
+3,939
New +$162K 0.03% 334

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Breakwater Capital Group's CYTK Position: Q2 2026 in Review

Breakwater Capital Group held its Cytokinetics (CYTK) position steady in Q2 2026 at 3,941 shares worth $336K. The position accounts for 0.04% of the portfolio, ranked #292.

Breakwater Capital Group first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Breakwater Capital Group held 3,941 shares of Cytokinetics worth $336K as of Q2 2026.
  • Breakwater Capital Group left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 0.04% of Breakwater Capital Group's portfolio in Q2 2026, its #292 holding.
  • Breakwater Capital Group first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Breakwater Capital Group's 13F filing for Q2 2026, filed 8 Jul 2026.